2021 年 11 巻 3 号 p. 16-25
Introduction: The relationship between in vivo immune status and clinical response to lenalidomide is unknown. Therefore, we examined the lymphocyte subsets, cytokines, and chemokines of patients with relapsed or refractory multiple myeloma (RRMM) treated with lenalidomide and low-dose dexamethasone (Ld) to determine the relationships between immune status, treatment efficacy, and safety.
Methods: This study included RRMM patients who had received one or two previous therapy sessions between August 2015 and March 2017 at the Hamamatsu University Hospital. We analyzed lymphocyte subsets, cytokines, and chemokines on days 1, 14, and 28 of the first Ld course.
Results: Twelve patients (6 men; median age: 69.5 years) were enrolled. The rate of partial response (PR) or better was 58%. There was no significant change in the lymphocyte count and its subset variation. MDC/CCL22 levels were continuously reduced after Ld therapy, but other cytokines and chemokines did not change at each measurement point. IP-10/CXCL10 levels on day 14 of Ld therapy were lower in patients with PR or better. We were unable to detect predictive factors associated with adverse events.
Conclusion: Our results suggest that IP-10/CXCL10 after Ld therapy could be a useful predictive factor for treatment response.
